A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
AZD9550 is in early development for the treatment of NASH, a type of liver disease that commonly affects overweight and obese patients who have T2DM. The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 in overweight and obese participants aged 18 through 65 years living with T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body.
Epistemonikos ID: a6a25789bbb7fac81af3fe0d50d1c6944a286962
First added on: May 15, 2024